{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["75(8)"],"submitter":["Huerga H"],"funding":["Harvard Medical School Center for Global Health Delivery"],"pubmed_abstract":["<h4>Background</h4>Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially poor risk-benefit ratio. Yet this combination is an important alternative for patients infected with strains of TB with complex drug resistance profiles or who cannot tolerate other therapies. We assessed safety and treatment outcomes of MDR/RR-TB patients receiving concomitant Bdq and Dlm, along with other second-line anti-TB drugs.<h4>Methods</h4>We conducted a multi-centric, prospective observational cohort study across 14 countries among patients receiving concomitant Bdq-Dlm treatment. Patients were recruited between April 2015 and September 2018 and were followed until the end of treatment. All serious adverse"],"journal":["Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"],"pagination":["1307-1314"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9555840"],"repository":["biostudies-literature"],"pubmed_title":["Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs."],"pmcid":["PMC9555840"],"pubmed_authors":["Huerga H","Mamsa S","Islam S","Kumsa A","Padayachee S","Ahmed S","Rashitov M","Khan PY","Yeghiazaryan L","Rich ML","Melikyan N","Leonovich O","Lachenal N","Varaine F","Osso E","Bastard M","Manzur-Ul-Alam M","Franke MF","Myint Z","Mitnick CD","Serobyan A","Grium Tefera D","Holtzman D","Salia G","Rafi Siddiqui M","Hewison C","Salahuddin N","Sanchez E","Seung KJ","Jacques Leblanc G","Vetushko D","Khan U"],"additional_accession":[]},"is_claimable":false,"name":"Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs.","description":"<h4>Background</h4>Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially poor risk-benefit ratio. Yet this combination is an important alternative for patients infected with strains of TB with complex drug resistance profiles or who cannot tolerate other therapies. We assessed safety and treatment outcomes of MDR/RR-TB patients receiving concomitant Bdq and Dlm, along with other second-line anti-TB drugs.<h4>Methods</h4>We conducted a multi-centric, prospective observational cohort study across 14 countries among patients receiving concomitant Bdq-Dlm treatment. Patients were recruited between April 2015 and September 2018 and were followed until the end of treatment. All serious adverse","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2025-04-04T19:23:02.153Z","creation":"2025-04-04T19:23:02.153Z"},"accession":"S-EPMC9555840","cross_references":{"pubmed":["35243494"],"doi":["10.1093/cid/ciac176"]}}